BIND Therapeutics

BIND Therapeutics is a biotechnology company developing novel targeted therapies primarily for the treatment of cancer. BIND is advancing and researching a tumor treatment drug called Accurins, designed to target tumor cells and tissues at the cellular and molecular levels. By enhancing drug concentration at the target site, Accurins aim to achieve better therapeutic effects on tumors while reducing the exposure of healthy tissues and cells to the drug, thereby minimizing harm to healthy tissues. Our leading candidate drug, BIND-014, is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC) and metastatic castration-resistant prostate cancer (mCRPC).